logo
← Back to RNS Announcements

IBT half-yearly report

During the six months to 29 February 2016, the net assets value (NAV) per Ordinary share of IBT fell by 17.7% from 585.1p to 481.7p. Over the same period, the Ordinary share price of IBT fell by 22.9% from 551.5p to 425.0p. This compares with a decline in the NASDAQ Biotechnology Index (NBI) of 18.0% and a fall in the FTSE All-Share Index of 1.2%.

Published on 19th April 2016

Science background with molecule or atom Abstract structure for Science or medical background
Science background with molecule or atom Abstract structure for Science or medical background

Disclaimer

The information on this website may only be suitable for certain types of investors and is not intended to be used or relied upon by any other person.

An investment with IBT may contain significant risks and is intended only for sophisticated investors who meet certain eligibility criteria.

The material on this website is intended to be viewed only by persons resident in the EEA.

The information on this website is not an offer to sell or a solicitation of an offer and does not constitute investment advice.

No representation, warranty or undertaking, express or implied, is given as to the accuracy or completeness of the information or opinions contained therein.

The information on this website may constitute financial promotion for the purposes of the Financial Services and Markets Act 2000 (“FSMA”).


I do not accept →